These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28039077)

  • 1. Pharmacokinetics of tiotropium administered by Respimat
    Sharma A; Kerstjens HA; Aalbers R; Moroni-Zentgraf P; Weber B; Dahl R
    Pulm Pharmacol Ther; 2017 Feb; 42():25-32. PubMed ID: 28039077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
    Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
    AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis.
    Konstan MW; Sharma A; Moroni-Zentgraf P; Wang F; Koker P
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):137-44. PubMed ID: 25380193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
    Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
    J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat
    Mansfield L; Duong-Quy S; Craig T
    Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis.
    Sharma A; Geller DE; Moroni-Zentgraf P; Kattenbeck S; Schmid M; Boland K; Rapp B; Konstan MW; Ratjen F; Elborn JS; Koker P
    Pulm Pharmacol Ther; 2014 Dec; 29(2):217-23. PubMed ID: 25161072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
    Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
    Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiotropium Respimat Is Effective for the Treatment of Asthma at a Dose Lower Than That for Chronic Obstructive Pulmonary Disease.
    Chin SJ; Durmowicz AG; Chowdhury BA
    Ann Am Thorac Soc; 2016 Feb; 13(2):173-9. PubMed ID: 26650145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
    Hodder R; Pavia D; Lee A; Bateman E
    Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease.
    Singh D; Ravi A; Kane K; Schmalbach T; Hava DL
    Br J Clin Pharmacol; 2018 Sep; 84(9):2097-2105. PubMed ID: 29790581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
    Ichinose M; Fujimoto T; Fukuchi Y
    Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.
    Hamelmann E; Bateman ED; Vogelberg C; Szefler SJ; Vandewalker M; Moroni-Zentgraf P; Avis M; Unseld A; Engel M; Boner AL
    J Allergy Clin Immunol; 2016 Aug; 138(2):441-450.e8. PubMed ID: 26960245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.